
Cipla

Working at Cipla
Company Summary
Overall Rating

5% above

Highly rated for 
Salary, Skill development, Work-life balance
Work Policy




Top Employees Benefits
About Cipla

At Cipla, we constantly work towards ensuring access to high quality and affordable medicines to support patients in need. Which is why, we have been trusted by health care professionals and patients across geographies for the last 8 decades.
Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.
For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of Caring for Life and deep-rooted community links wherever it is present, make it a partner of choice for global health bodies and stakeholders.

ABECA - AmbitionBox Employee Choice Awards





Cipla Ratings
Overall Rating





Category Ratings
Salary
Skill development
Work-life balance
Company culture
Job security
Work satisfaction
Promotions
Work Policy at Cipla



Cipla Reviews
Top mentions in Cipla Reviews
Compare Cipla with Similar Companies
![]() | ![]() Change Company | ![]() Change Company | ![]() Change Company | |
---|---|---|---|---|
Overall Rating | 4.1/5 based on 7.6k reviews | 4.0/5 based on 7.4k reviews | 4.1/5 based on 6.7k reviews | 4.1/5 based on 6.8k reviews |
Highly Rated for | Skill development Salary Work-life balance | Skill development Salary Work-life balance | Skill development Company culture Work-life balance | Salary Skill development Job security |
Critically Rated for | ![]() No critically rated category | Promotions | ![]() No critically rated category | ![]() No critically rated category |
Primary Work Policy | Work from office 73% employees reported | Work from office 74% employees reported | Work from office 82% employees reported | Work from office 67% employees reported |
Rating by Women Employees | 4.0 Good rated by 778 women | 3.9 Good rated by 855 women | 4.1 Good rated by 415 women | 4.0 Good rated by 516 women |
Rating by Men Employees | 4.1 Good rated by 6.5k men | 4.0 Good rated by 6.2k men | 4.1 Good rated by 6k men | 4.1 Good rated by 5.9k men |
Job security | 3.7 Good | 3.5 Good | 3.7 Good | 3.9 Good |
Cipla Salaries
Deputy Manager

Area Business Manager

Therapy Manager

Medical Representative

Territory Manager

Regional Business Manager

Production Officer

Area Sales Manager

Scientific Business Manager

Maintenance Engineer

Cipla Interview Questions
Cipla Jobs
Cipla News
Nifty Prediction today – Aug 6, 2025: Index might see some more moderation
- Nifty index shows a bearish trend with more decliners than advancers. Top gainers include Trent and Adani Ports, while top losers are Cipla, Wipro, HCL Technologies, and Infosys.
- Volatility has increased as seen in the rise of India VIX by 2.2%. Mid- and small-cap indices along with most sectoral indices are down, indicating a bearish bias.
- Nifty futures opened flat at 24,708 and are currently around the same level. The intraday resistance is at 24,730 with support levels at 24,600 and 24,550.
- Recommendation: Short Nifty futures at 24,700 with targets at 24,550 and stop-loss at 24,750. A bullish rally above 24,730 could shift the trend. Supports: 24,600, 24,550. Resistance: 24,730, 25,000.
Stock Market Highlights: Nifty, Sensex Settle Lower On Tariff Jitters; RIL, Infosys, Cipla Top Drags
- The Nifty 50 and BSE Sensex closed lower amid tariff jitters, with Nifty ending down 0.30% and Sensex down 0.38%.
- Top drags on the index were RIL, Infosys, and Cipla, while gains were seen in shares of Titan, IndusInd Bank, SBI Life, Maruti Suzuki, and Trent.
- Five out of 12 sectors ended positively, with Nifty Defence, Auto, Metal, Consumption showing gains, while sectors like Nifty Oil and gas, Pharma, FMCG, IT, and Bank suffered losses.
- Market breadth favored sellers with BSE Midcap and Smallcap indices ending lower, and around 2,294 stocks declining compared to 1,752 advancing.

Sensex down 300 pts, pharma index down 3%, Sun Pharma, Dr Reddy’s Lab, Cipla among top losers
- Sensex and Nifty declined with Sensex down by 334.49 points (0.41%) and Nifty 50 by 125.50 points (0.51%) as of 12.41 pm.
- Midcap and smallcap indexes decreased by 0.62% and 0.74% respectively with a continuation of the trend likely for smallcaps due to high valuations.
- Pharma, healthcare, IT, oil & gas, and metal stocks faced losses. Sun Pharma, Dr Reddy’s Lab, and Cipla were among the top losers.
- Gainers on Nifty 50 included Eicher Motors, Trent, and Asian Paints, while stocks like Sun Pharma, Dr. Reddy’s Lab, and Cipla were major laggards.

Markets extend losses at mid-session as pharma stocks lead decline amid Trump tariff concerns
- Pharmaceutical stocks, including Sun Pharma, Dr Reddy's Laboratories, and Cipla, faced significant losses amid concerns over potential US trade restrictions.
- Steel and energy stocks were also under pressure, with Tata Steel and ONGC declining due to investor worries over trade tensions.
- Despite the market decline, select consumer and auto stocks like Trent, Eicher Motors, and Asian Paints saw gains, offering some relief.
- The market breadth remained weak, with Nifty Next 50 and Nifty Midcap 100 falling, while the financial services sector showed relative resilience.

Buy, Sell Or Hold? Osho Krishan Recommends Sona BLW, Cipla, PG Electroplast
- Osho Krishan, Chief Manager at Angel One, recommended buying Sona BLW Precision Forgings Ltd, Cipla Ltd, and PG Electroplast Ltd for short-term trading opportunities.
- Specific entry levels, stop-loss thresholds, and target prices were provided for each recommended stock.
- Sona BLW Precision Forgings Ltd was advised for buying at the current market price with a stop-loss at Rs 476 and a target of Rs 515.
- Cipla Ltd was suggested as a buy at the current market price with a stop-loss at Rs 1,465 and a target of Rs 1,520.

Five Stocks To Buy: Bandhan Bank, Cipla, Sona BLW, Rain Industries, Laurus Labs
- Analysts recommend buying stocks such as Bandhan Bank, Cipla, Sona BLW, Rain Industries, and Laurus Labs for Friday's trade session.
- Recommendations were provided by analysts like Osho Krishnan, Nilesh Jain, and Akshay P Bhagwat.
- Target prices and stop losses were given for each stock, with potential upside percentages mentioned.
- The stocks selected span across financial services, pharma, chemicals, and automobile component sectors.

Stock Market Live: GIFT Nifty Implies Negative Open; Vedanta, Hindalco, Cipla, Lupin, Dr. Reddy's In Focus
- Indian markets are expected to open lower due to weak global cues with the Nifty 50 likely to have support at 25,400 and resistance at 25,600.
- Global markets, including Asia and the US, experienced declines following announcements by US President Donald Trump of tariffs on copper and pharmaceutical imports, leading to a negative sentiment in the markets.
- The GIFT Nifty was trading down, indicating a negative open. Investors might focus on companies like JSW Steel, Tata Steel, Seamec, Dixon Technology, and Rail Vikas Nigam for news impact.
- The Nifty 50 and BSE Sensex closed higher on the previous day, influenced by Kotak Mahindra Bank and HDFC Bank performance, amidst trade deal uncertainties between the US and India.

Market Experts' LIVE Stock Recommendations: Buy Varun Beverage, Sell Tata Motors, Hold Cipla
- Market experts provide live stock recommendations: Buy Varun Beverage, Sell Tata Motors, Hold Cipla.
- Investors may take interest in pharmaceutical stocks due to fear of increased geopolitical tension.
- Oil refining companies are in focus as oil prices rebound amid Israel-Iran tensions.
- Hensex Securities suggests exiting Tata Motors due to limited upside potential in the short and long term.
- Globe Capital advises holding Cipla, noting its stable performance with potential to move towards Rs 1,650.
- Hensex Securities recommends buying Varun Beverages for long-term prospects, suggesting gradual accumulation over time.

Buy, Sell Or Hold: Cipla, Premier Energies, Bajaj Finance, Tata Motors, Tilaknagar Industries — Ask Profit
- Analysts provide insights on stock recommendations for various companies including Cipla, Premier Energies, Bajaj Finance, Tata Motors, Tilaknagar Industries, and Varun Beverages.
- Gaurav Sharma recommends holding Cipla shares at the current price as the stock is stable.
- Mahesh Ojha advises avoiding Premier Energies for now and suggests a favorable price for entry.
- Gaurav suggests refraining from making fresh buys in Bajaj Finance, while existing investors should maintain their positions around Rs 880-860 range.
- Mahesh recommends exiting Tata Motors due to limited potential and cautious long-term outlook.
- For Tilaknagar Industries, Mahesh suggests booking profits in the near term or aiming for a target price in the long run.
- Gaurav advises waiting to enter Camlin Fine Sciences stock at a potential correction around Rs 270-280.
- Mahesh considers Varun Beverages promising for long-term investment with gradual accumulation.
- Investment advisers' views on NDTV Profit are personal recommendations and viewers are urged to consult with their financial advisers.

Pharma, Chemicals Drive India’s $5.9 Billion Exports To Canada In 2024
- India's bilateral trade in goods with Canada reached $9.8 billion in 2024, with India exporting $5.9 billion and importing $3.9 billion.
- Bilateral services trade between India and Canada stood at $13.7 billion in 2024, with India exporting services worth $2.58 billion.
- Over 600 Canadian companies operate in India, while Indian companies are active in Canada in various sectors.
- India's pharmaceutical exports to Canada increased by 20.4% in 2024 to $511.79 million.
- Key Indian drugmakers like Dr. Reddy's, Sun Pharma, and Cipla have strengthened their presence in Canada.
- India exported $225.91 million worth of organic chemicals to Canada in 2024.
- Canada remains a key supplier of raw materials like potash to India, with imports seeing a decline from April to December 2024.
- Indian firms like Coromandel International and Chambal Fertilizers have agreements with Canadian exporters for potash supply.


Cipla Subsidiaries

Cipla Health
Compare Cipla with




















Contribute & help others!
Companies Similar to Cipla












Cipla FAQs


Reviews
Interviews
Salaries
Users

